Ariana Pelosci, associate editor for CancerNetwork®, has been with the team since June 2021. She specializes both in web and print, and runs the social media for CancerNetwork®.
She is a graduate of the University of Delaware, where she studied Media Communications and minored in journalism and marketing. At heart, she is a Jersey girl, and you can always find her down the shore during her free time.
Ariana loves to read, specifically historical or contemporary fiction. Follow Ariana on Twitter @APelosci or email her at apelosci@mjhlifesciences.com.
Daratumumab Combo Yields Responses in Pretreated R/R Multiple Myeloma
June 9th 2023Results from the phase 2 DARIA trial found an improved overall response rate in patients given daratumumab, ixazomib, and dexamethasone with relapsed/refractory multiple myeloma who were previously treated with lenalidomide.
Ruxolitinib Appears to Yields Superior Responses in Polycythemia Vera Subtype
May 18th 2023Findings from the phase 2 MAJIC-PV trial highlight a superior event-free survival and overall survival following ruxolitinib vs best available treatment in patients with polycythemia vera who were intolerant/resistant to hydroxycarbamide.
Exemestane at 25 mg Noninferior in Reducing Serum Estradiol in Breast Cancer
April 24th 2023Investigators cite the need for further study of the 25 mg, 3 times weekly exemestane dosing schedule in prevention studies among those with post-menopausal, stage 0 to II estrogen receptor–positive breast cancer who can’t tolerate daily adjuvant treatment.
Enfortumab Vedotin Combo Gets Accelerated FDA Nod for Urothelial Cancer
April 3rd 2023Results from cohort K of the phase 1b/2 KEYNOTE-869 trial led to the accelerated approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial cancer who cannot receive cisplatin-based chemotherapy.
FDA Gives Full Approval to Pembrolizumab in dMMR/MSI-H Solid Tumors
March 29th 2023Based on results from the phase 2 KEYNOTE-158, KEYNOTE-164, and KEYNOTE-051 trials, the FDA has given full approval to pembrolizumab for patients with microsatellite instability-high or mismatch repair deficient solid tumors.
BXCL701/Pembrolizumab Yields Durable Responses in Prostate Cancer Subtype
March 10th 2023All patients with platinum-resistant, small-cell neuroendocrine prostate cancer who responded to treatment with BXCL701 plus pembrolizumab were microsatellite stable and/or tumor mutational burden–low with a low probability of response to pembrolizumab.
FDA ODAC Votes in Favor of Polatuzumab Vedotin in Previously Untreated DLBCL
March 10th 2023Polatuzumab vedotin-piiq plus R-CHP was found to produce clinical efficacy in phase 3 POLARIX trial in patients with previously untreated diffuse large B-cell lymphoma, leading to an 11-to-2 vote from the FDA’s Oncologic Drug Advisory Committee.